The Treatment-resistant Hypertension Market to Grow Positively with a CAGR of 3.2% In The 7MM During The Study Period (2019-32) | DelveInsight

DelveInsight's analysts estimate that the Treatment-resistant Hypertension market is expected to show positive growth, mainly attributed to increased prevalence and the anticipated launch of novel therapies by the key companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharmaduring, and others the forecast period (2019–2032). 

LAS VEGAS, April 26, 2022 /PRNewswire/ -- DelveInsight's Treatment-resistant Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, Treatment-resistant Hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Treatment-resistant Hypertension Market

• As per DelveInsight analysis, the Treatment-resistant Hypertension market size was over USD 13.4 billion in 2021, which is further expected to increase by 2032.
• As per the estimates, the total Treatment-resistant Hypertension prevalent population in the 7MM was more than 16 million in 2021.
• Key Treatment-resistant Hypertension companies such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others are currently working to develop drugs for Resistant Hypertension which can be available in the Treatment-resistant Hypertension market in the upcoming years.
• The Treatment-resistant Hypertension therapies in the pipeline include Aprocitentan, Firibastat (QGC001), CIN-107, IONIS-AGT-LRx, and others.
• The current understanding of Treatment-resistant hypertension has improved in recent decades, leading to growing awareness, improved management, and better outcomes, thereby driving the Treatment-resistant Hypertension market.

Discover more about therapies set to grab major Treatment-resistant Hypertension market share @ Treatment-resistant Hypertension Market Landscape

Treatment-resistant Hypertension Overview

Resistant Hypertension (RHTN) is defined as uncontrolled blood pressure despite the use of three antihypertensive agents of different classes, including diuretic, typically thiazide-like, a long-acting calcium channel blocker, and a renin-angiotensin system blocker, either an ACE (angiotensin-converting enzyme) inhibitor or an ARB (angiotensin receptor blocker), at maximal or maximally tolerated

Secondary causes of Resistant Hypertension include Obstructive Sleep Apnea, Renal Artery Stenosis, Renal Parenchymal Disease, and Primary Aldosteronism, along with some uncommon Resistant Hypertension causes such as Pheochromocytoma, Cushing's disease, thyroid, and parathyroid dysfunction, and aortic coarctation.

Resistant Hypertension symptoms may arise when blood pressure initially begins to increase or during a hypertensive crisis when levels are extremely high. Common Resistant Hypertension symptoms include headache, shortness of breath, chest pain, and nosebleeds. The Resistant Hypertension diagnosis requires the use of reliable blood pressure technology to confirm consistently raised blood pressure readings. Pseudo Resistance, such as a lack of blood pressure control owing to poor medication adherence or white coat hypertension, must be ruled out.

Learn more about resistant hypertension management @ Treatment-resistant Hypertension Guidelines

Treatment-resistant Hypertension Epidemiology Segmentation

As per DelveInsight, the total Treatment-resistant Hypertension prevalent population in the 7MM was more than 16 million in 2021.

Among EU5 countries, Germany has the highest prevalent population of Treatment-resistant Hypertension in 2021.

The Treatment-resistant Hypertension Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Total Prevalent Cases of Treatment-resistant Hypertension
• Age-specific Cases of Treatment-resistant Hypertension
• Gender-specific Cases of Treatment-resistant Hypertension

Download the report to understand which factors are driving Treatment-resistant Hypertension epidemiology trends @ Treatment-resistant Hypertension Epidemiological Insights

Treatment-resistant Hypertension Treatment Market

The treatment for Resistant Hypertension is focused on the addition of fourth-line therapy where blood pressure is not controlled by treatment with three drugs, described by NICE as A + C + D: that is, an ACE inhibitor or an angiotensin II receptor blocker (A), a calcium channel antagonist (C), and a thiazide or thiazide-like diuretic (D). The most recommended drug therapy for Resistant Hypertension as a fourth-line agent is spironolactone in patients with potassium of <4.5 mmol/L who are likely to respond to a mineralocorticoid receptor blocker. For patients with potassium of >4.5 mmol/L, it is recommended that the existing diuretic (thiazide or thiazide-like) be doubled.

Nonpharmacological therapies for Resistant Hypertension treatment include weight loss, regular exercise, a high-fiber, low-fat, low-salt diet, and alcohol moderation, which should be supported when appropriate. Potentially interfering pharmacological substances should be discontinued or reduced to clinically acceptable levels. Obstructive Sleep Apnea should be treated if it is present.

Furthermore, with a few promising drugs for Resistant Hypertension in the pipeline, the Treatment-resistant Hypertension market size is projected to grow. Among the emerging therapies, the most promising ones include firibastat (Quantum Genomics) – a Phase III Glutamyl aminopeptidase inhibitors, aprocitentan (Idorsia Pharmaceutical) – a Phase III endothelin receptor antagonists, and CIN-107 – Phase II aldosterone synthase inhibitor (ASI), among others.

Discover more about therapy set to grab substantial Treatment-resistant Hypertension market share @ Resistant Hypertension Treatment 

Treatment-resistant Hypertension Pipeline Therapies and Key Players

• Aprocitentan: Idorsia Ltd / Janssen Biotech
• Firibastat (QGC001): Quantum Genomics SA
• CIN-107: CinCor Pharma
• IONIS-AGT-LRx: Ionis Pharmaceuticals

To know about more new drugs for Treatment-resistant Hypertension treatment visit @ Treatment-resistant Hypertension Medications

Treatment-resistant Hypertension Market Dynamics

The dynamics of the Treatment-resistant Hypertension market are anticipated to change with the launch of first-in-class drugs for resistant hypertension with novel MoA, such as aprocitentan, CIN-107, and others. Despite being the first-choice Resistant Hypertension medicine as an add-on therapy option for RHTN patients, there is an urgent unmet need for alternative therapeutic choices with a better side-effect profile, innovative MoA, simplicity of administration, etc which will drive the Treatment-resistant Hypertension market.

However, the high resistant hypertension prevalence in the elderly population complicates diagnosis and adherence to antihypertensive medication. As a result, in high-risk RHTN patients, a high prevalence of adverse events such as cardiovascular events, stroke, and hyperkalemia leads to a high death rate, thereby limiting the growth of the Treatment-resistant Hypertension market. In addition, there is a scarcity of real-time data on the epidemiology of RHTN in a given population. Furthermore, physician inertia (reluctance to prescribe new treatments) in the mature Treatment-resistant Hypertension market is expected to have an influence on the acceptance of newer therapies.

Moreover, lifestyle factors such as obesity and increased body mass index, and excessive alcohol and salt intake contribute to the presence of Resistant Hypertension, thus impeding Treatment-resistant Hypertension market growth. Several drugs and substances such as Nonsteroidal anti-inflammatory drugs (NSAIDs) probably represent the most common agents in worsening BP control. The use of NSAIDs increases BP levels and can blunt the effect of various antihypertensive drugs such as diuretics, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, which in turn act as a barrier to the Treatment-resistant Hypertension market growth.

Furthermore, several other factors impacting the Treatment-resistant Hypertension market growth include Obstructive Sleep Apnea, Primary Aldosteronism, and Chronic Kidney Disease. They represent the most common secondary causes of Resistant Hypertension, whereas several other conditions may also be responsible for treatment resistance.

Scope of the Treatment-resistant Hypertension Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Treatment-resistant Hypertension Companies: Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, and others
• Key Treatment-resistant Hypertension Pipeline Therapies: Aprocitentan, Firibastat (QGC001), CIN-107, IONIS-AGT-LRx, and others
• Treatment-resistant Hypertension Therapeutic Assessment: Treatment-resistant Hypertension current marketed and emerging therapies
• Treatment-resistant Hypertension Market Dynamics: Treatment-resistant Hypertension market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Treatment-resistant Hypertension Market Access and Reimbursement

Discover more about the future Treatment-resistant Hypertension market share of treatment therapies @ Best Medication for Resistant Hypertension Treatment

Table of Contents

Get in touch with our Business executive @ Healthcare Due Diligence Services 

Related Reports

Treatment-resistant Hypertension Epidemiology

Treatment-resistant Hypertension Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Treatment-resistant Hypertension epidemiology in the 7MM.

Treatment-resistant Hypertension Pipeline

Treatment-resistant Hypertension Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Treatment-resistant Hypertension companies involved such as Idorsia Ltd, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, among others.

Hypertension Pipeline

Hypertension Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Hypertension companies involved such as Janssen Biotech, Quantum Genomics, CinCor Pharma, Vifor Pharma, KBP Biosciences, among others.

Narcolepsy Market

Narcolepsy Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Narcolepsy companies such as Centessa Pharmaceuticals, Ono Pharma, Harmony Biosciences, Reset Therapeutics, among others.

Sleep Apnea Market

Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Sleep Apnea companies such as Apnimed, Therapix Biosciences, Eisai, Idorsia Pharmaceuticals, among others.

Sleep Apnea Implants Market

Sleep Apnea Implants Market Insight, Competitive Landscape, and Market Forecast, 2026 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Sleep Apnea Implants companies such as Inspire Medical Systems, LinguaFlex, LivaNova PLC, Medtronic, Respicardia Inc., among others.

Other Trending Reports

Follicular Lymphoma Market

Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Follicular Lymphoma companies such as Merck, Genentech, Novartis, among others.

Pars Plantis Market

Pars Plantis Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Pars Plantis companies in the domain.

Metrorrhagia Market

Metrorrhagia Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Metrorrhagia companies in the domain.

Cocaine Use Disorder Market

Cocaine Use Disorder Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Cocaine Use Disorder companies such as Novartis, Saniona, KemPharm, among others.

Wegener's Granulomatosis Market

Wegener's Granulomatosis Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key Wegener's Granulomatosis companies such as InflaRx, Roche, BMS, among others.

Related Healthcare Blogs

Treatment-resistant Hypertension Market

Pulmonary Arterial Hypertension Treatment Landscape

Narcolepsy Treatment Market

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg